Physician profile
Manzar Y Rajput
NPI 1851358527
$612,193.01
in general payments reported to CMS, 2019-2025
21 companies · $265K in 2025
The $265K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,867 · 2020: $6,276 · 2021: $4,928 · 2022: $19K · 2023: $94K · 2024: $214K · 2025: $265K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $371K · Consulting Fee: $89K · Honoraria: $64K · Travel and Lodging: $27K · Food and Beverage: $22K · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $370,554.00 |
| Consulting Fee | $88,646.25 |
| Honoraria | $64,450.00 |
| Travel and Lodging | $27,287.86 |
| Food and Beverage | $21,606.35 |
| Education | $180.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $186,162.14 | 2021-2025 | |
| Axsome Therapeutics, INC. | $140,246.14 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $123,433.73 | 2022-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $73,269.56 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $51,158.34 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Idorsia Pharmaceuticals US INC | $19,616.40 | 2022-2023 | Quviviq |
| Allergan, INC. | $14,914.01 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $1,203.95 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $526.50 | 2020-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $517.61 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $275.69 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $209.80 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $158.84 | 2020-2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $148.25 | 2023-2025 | Qelbree, Qelbree |
| Brainsway USA INC | $98.59 | 2024 | Brainsway Deep Tms System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $59.44 | 2019-2021 | |
| Corium, LLC | $58.20 | 2023 | Azstarys |
| Indivior INC. | $44.44 | 2022-2024 | Perseris |
| Validus Pharmaceuticals LLC | $38.33 | 2023-2025 | Raldesy, Equetro |
| Bausch Health US, LLC | $35.18 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.87 | 2024 | Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manzar Rajput listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.